Search

Your search keyword '"Lampertico P."' showing total 1,570 results

Search Constraints

Start Over You searched for: Author "Lampertico P." Remove constraint Author: "Lampertico P."
1,570 results on '"Lampertico P."'

Search Results

51. Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B

52. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

53. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

54. X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

55. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

56. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

57. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting

58. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

59. Development and validation of an artificial intelligence PIVKA-II-based model for the prediction of hepatocellular carcinoma development in patients with HCV-related cirrhosis successfully treated with direct-acting antivirals

60. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

62. Hepatitis D: Looking Back, Looking Forward, Seeing the Reward and the Promise.

66. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion

67. Patient-Reported Symptoms and Sequelae 12 Months After COVID-19 in Hospitalized Adults: A Multicenter Long-Term Follow-Up Study

68. The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia

69. Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination

70. Location and allocation: inequity of access to liver transplantation for patients with severe acute‐on‐chronic liver failure in Europe

71. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B

72. Digestive diseases. 2022-2025 edition

73. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort

74. Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study

75. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts

76. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study

77. Reply to: Correspondence on “High rates of 30-day mortality in patients with cirrhosis and COVID-19”

78. Pulmonary Resection for Metastasis of Hepatocellular Carcinoma Recurring After Liver Transplant: An Italian Multicenter Experience

79. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study

80. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting

81. Relationship between recipient/donor features and liver stiffness measurement in the first year after liver transplantation.

82. Characterization of transcriptional and functional CD8 T cell heterogeneity to design individualized correction strategies for chronic HBV infection.

83. Impact of liver transplantation on spleen stiffness: early findings from a single-centre study.

84. Liver transplants in untreated vs Bulevirtide-treated patients with chronic Hepatits Delta: a cross-sectional, intrahepatic analysis.

85. Ultrasound muscular thickness-based model to identify sarcopenia in patients with portal hypertension (PH): a cross-sectional single-center observational study.

86. Hepatitis delta virus (hdv) replication through hbv integrants in hcc recurrence after liver transplantation.

87. Thrombus generation under flow conditions in patients with cirrhosis and thrombocytopenia: the CirTAS-study.

88. Epidemiological, virological and clinical profile of HBsAg positive individuals in Italian hospital settings: interim results of the HBV/HDV PITER cohort

89. Switching tdf treated patients to taf is a safe and effective strategy even in difficult-to-manage elderly patients with hbv-related cirrhosis and significant comorbidities: a real-life prospective study

90. Divergent patterns of hbv-rna and hbcrag levels in untreated chronic hepatitis delta: a large european cross-sectional study

95. Effectiveness and safety of bulevirtide monotherapy 2 mg/die in hdv patients with compensated cirrhosis and clinically significant portal hypertension

96. Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study

97. Humoral, cellular, clinical responses and safety of two doses of SARS-CoV-2 Messenger RNA vaccine in patients with compensated and decompensated cirrhosis: a long-term single center prospective study

98. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

99. Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib

Catalog

Books, media, physical & digital resources